N'-nitrosonornicotine (NNN) (NNN)

N'-nitrosonornicotine (NNN) is a potent tobacco-specific nitrosamine (TSNA) and is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC, 2012). It is primarily formed during the curing and processing of tobacco through the nitrosation of nornicotine, a secondary tobacco alkaloid (PubChem, CID 40452). NNN is not a therapeutic target; rather, it is a hazardous xenobiotic that requires metabolic activation to exert its carcinogenic effects (Hecht, 1998). This activation is primarily mediated by cytochrome P450 enzymes, such as CYP2A13 and CYP2A6, which convert NNN into reactive electrophilic intermediates (Xue et al., 2014). These intermediates react with DNA to form covalent adducts, such as pyridyloxobutyl (POB) adducts, which can lead to permanent mutations in critical genes like KRAS and TP53 (Hecht, 1998). Additionally, NNN has been shown to bind to and activate nicotinic acetylcholine receptors (nAChRs), which may contribute to tumor promotion by stimulating cell proliferation and survival pathways (Schuller, 2009). Chronic exposure to NNN is strongly associated with the development of esophageal, oral cavity, and lung cancers in tobacco users (IARC, 2012).

Other names

1-Nitroso-2-(3-pyridyl)pyrrolidineNitrosonornicotine1'-NitrosonornicotineNNN

N'-nitrosonornicotine (NNN) acts as a pro-carcinogen that requires metabolic activation by cytochrome P450 enzymes (e.g., CYP2A13, CYP2A6) to form reactive electrophilic intermediates that create covalent DNA adducts, leading to genomic instability and oncogenic mutations (Hecht, 1998; Xue et al., 2014).